Quick answer: the evidence for hyaluronic acid knee injections is weaker than the marketing suggests, and most major guidelines now advise against routine use. The largest analysis, published in The BMJ in 2022, pooled 169 trials and over 21,000 participants and found a pain reduction that fell below the threshold patients can actually notice, alongside a higher rate of serious adverse events than placebo. AAOS, the American College of Rheumatology and NICE all recommend against them. A minority of guidelines still endorse them conditionally, and some individuals do report relief — so this is a decision worth making with clear eyes rather than a treatment to assume works.
This article is general information, not medical advice about your knee. Your orthopaedic surgeon knows your imaging, your history and what you have already tried. Use this to have a better conversation, not to overrule them.
What the Guidelines Actually Say
This is the part most pages on this topic leave out, and it is the single most useful thing to know before agreeing to a course.
| Guideline | Position on HA for knee OA |
|---|---|
| AAOS (American Academy of Orthopaedic Surgeons), 2021 | Not recommended for routine use, moderate strength. Also omitted entirely from its 2022 Appropriate Use Criteria |
| ACR / Arthritis Foundation, 2019 | Conditionally recommends against for the knee. Strongly against for the hip |
| NICE (UK), NG226, 2022 | “Do not offer” hyaluronan injections |
| OARSI, 2019 | Conditionally recommended for the knee depending on the patient’s comorbidity profile. Not recommended for the hip |
| US VA / Department of Defense, 2020 | Conditional recommendation for selected patients |
So the guidelines genuinely conflict — but the weight has shifted decisively against routine use over the past decade. AAOS was unable to make a recommendation in 2008, moved to a strong recommendation against in 2013, and has maintained that position since.
If your surgeon recommends HA, that is not necessarily wrong — clinicians reasonably treat individual patients rather than averages, and a few guidelines still support selective use. But it is entirely fair to ask why they are recommending something several major bodies advise against, and a good clinician will have an answer.
What the Research Found
The BMJ 2022 analysis
The most comprehensive assessment to date. Pereira and colleagues pooled 169 randomised trials involving more than 21,000 participants and concluded:
- The pain reduction versus placebo was small and fell below the minimal clinically important difference — meaning the average patient would not perceive it as a meaningful change.
- Serious adverse events were more common with HA than placebo, at roughly 3.7 percent versus 2.5 percent.
- The authors concluded the evidence does not support broad use for knee osteoarthritis.
Understanding “statistically significant but below the clinical threshold” matters here. It means the effect is probably real but too small to notice — which is a very different proposition when you are paying for a course of injections.
The counterarguments, fairly stated
- Subgroup signals in earlier-stage disease. Some analyses suggest patients with mild to moderate OA may respond better than the pooled average. Subgroup findings are less reliable than overall results, but they are not nothing.
- Molecular weight may matter. Network meta-analyses have explored whether high molecular weight or cross-linked products perform better than low molecular weight ones. The question is unsettled.
- Individual response varies. Pooled averages hide people at both ends. Some patients genuinely report months of relief.
- A large placebo effect is real relief. Injection procedures produce substantial placebo responses. That is a genuine improvement in how someone feels, even though it is not the drug working — worth being honest about in both directions.
What Hyaluronic Acid Is and How It Is Given
Hyaluronic acid occurs naturally in synovial fluid and cartilage, where it acts as a lubricant and shock absorber. In osteoarthritis its concentration and molecular weight fall, leaving thinner fluid. Viscosupplementation injects a manufactured version into the joint to temporarily restore those properties. You may hear it called gel injections, and brand names include Synvisc, Durolane, Supartz and Euflexxa.
It is given as a series of three to five weekly injections, or as a single larger-volume injection with newer formulations. Ultrasound or fluoroscopic guidance improves accuracy of placement.
The proposed mechanisms — better lubrication, reduced inflammation, effects on pain receptors, possible cartilage protection — are biologically plausible. The difficulty has never been the theory. It is that trials have struggled to show the theory translating into relief patients can feel.
How It Compares to the Alternatives
| Option | Evidence | Notes |
|---|---|---|
| Exercise and strengthening | Strong. First-line in every guideline | The most effective non-surgical treatment. Cheap and underused |
| Weight management | Strong where weight is a factor | Reduces load and systemic inflammation |
| Corticosteroid injection | Moderate, short-term | Faster relief, typically weeks to a few months. Repeated use has its own concerns |
| Hyaluronic acid | Weak. Below clinical threshold in pooled analysis | Most guidelines advise against routine use |
| PRP | Emerging and mixed | Some trials favour it over HA; preparation methods vary widely, which complicates comparison. See our PRP guide |
| Knee replacement | Strong for advanced disease | Considered when conservative options are exhausted and function is significantly limited |
The uncomfortable comparison: a structured exercise programme has better evidence than any injection and costs a fraction as much, yet is consistently under-prescribed. If you have not done a supervised strengthening programme properly, that is the higher-value place to start. See our guides to knee osteoarthritis treatment and knee strengthening exercises.
Cost and Whether It Is Justified
HA injections are expensive relative to their evidence base, and coverage varies considerably. Many insurers restrict or exclude them, and some health systems have withdrawn funding on the basis of the guidelines above. Costs differ widely by country, brand, whether the protocol is single or multi-injection, and whether imaging guidance is used — so ask for the total cost of a full course, not the price of one injection.
Questions worth asking before committing:
- What is the total cost of the full course, including any repeat?
- Given that AAOS and NICE advise against routine use, what makes me a good candidate?
- What outcome would tell us it has worked, and by when?
- Have I completed a proper supervised exercise programme yet?
- Would a corticosteroid injection be a reasonable first step?
Who Responds Best, If You Proceed
Where benefit has been reported, it clusters in:
- Mild to moderate osteoarthritis, roughly Kellgren-Lawrence grade I to II, with cartilage still present
- Younger patients with less advanced structural change
- People who cannot take oral anti-inflammatories and have limited alternatives
- People not suitable for surgery, where the calculation shifts
Patients with grade III to IV disease and bone-on-bone contact consistently see least benefit. If your imaging shows advanced disease, expectations should be set accordingly.
Risks and Who Should Avoid Them
Generally well tolerated, though not risk-free — and the BMJ analysis found a higher rate of serious adverse events than placebo, which is why “it probably won’t help but it can’t hurt” is not an accurate summary.
- Injection site pain and swelling, usually settling within one to two days
- Pseudoseptic reaction, an uncommon severe inflammatory flare 24 to 72 hours after injection. It is not an infection but mimics one and needs assessment
- Joint infection (septic arthritis), rare but serious. Any hot, swollen, very painful knee with fever after an injection needs same-day medical assessment
- Allergic reaction, rare, and more relevant with avian-derived products if you have an egg or poultry allergy
Avoid if you have an active joint infection, a skin infection over the injection site, a significant effusion that has not been drained, a known allergy to hyaluronate or avian protein for those products, or are pregnant, where evidence is insufficient.
If You Go Ahead
- Tell your doctor about all medications, particularly anticoagulants
- Follow their advice on anti-inflammatory medication around the injection date
- Arrange transport home; the knee is often sore afterwards
- Avoid strenuous activity and prolonged standing for around 48 hours
- Keep doing the strengthening work. Injections without exercise reliably give shorter-lived relief, and the exercise is the part with the strong evidence
- Agree a review point in advance, so “did it work” gets an honest answer rather than drifting into another course
Frequently Asked Questions
The evidence is weaker than the marketing suggests. The largest analysis, published in The BMJ in 2022, pooled 169 randomised trials and over 21,000 participants and found the pain reduction versus placebo was small and fell below the minimal clinically important difference — meaning the average patient would not perceive it as meaningful. It also found more serious adverse events with HA than placebo. Some individuals do report relief, and subgroup analyses suggest earlier-stage disease may respond better.
Most major ones now advise against routine use. AAOS says they are not recommended for routine use in symptomatic knee osteoarthritis, the American College of Rheumatology conditionally recommends against them for the knee and strongly against for the hip, and NICE in the UK says do not offer them. OARSI and the US VA/Department of Defense still give conditional endorsements for selected patients, so guidelines do genuinely conflict — but the weight has shifted against routine use over the past decade.
Not necessarily. Clinicians treat individual patients rather than averages, some guidelines still support selective use, and your surgeon knows your imaging and history. But it is entirely reasonable to ask why they are recommending something AAOS and NICE advise against, what makes you a good candidate, what the full course costs, and whether you have completed a proper supervised exercise programme first. A good clinician will have answers.
Corticosteroid injections give faster relief, typically within days, lasting weeks to a few months, and have better guideline support for short-term symptom control. HA is slower in onset and its claimed longer duration is not consistently demonstrated across studies. Given that pooled analyses put HA benefit below the clinically meaningful threshold, a steroid injection is often the more reasonable first injection option — though repeated steroid use has its own concerns to discuss with your doctor.
Where benefit has been reported it clusters in mild to moderate osteoarthritis, roughly Kellgren-Lawrence grade I to II with cartilage still present, in younger patients, in people who cannot take oral anti-inflammatories, and in those not suitable for surgery. Patients with grade III to IV disease and bone-on-bone contact consistently see the least benefit, so expectations should be set accordingly if imaging shows advanced change.
Generally well tolerated, but not risk-free — the BMJ analysis found serious adverse events were more common with HA than placebo, at roughly 3.7 percent versus 2.5 percent. Common effects are injection site pain and swelling settling in a day or two. A pseudoseptic reaction, an uncommon severe inflammatory flare 24 to 72 hours afterwards, mimics infection and needs assessment. Joint infection is rare but serious: a hot, swollen, very painful knee with fever after an injection needs same-day medical attention.
Structured exercise and strengthening, which is first-line in every major guideline and has considerably stronger evidence than any injection, at a fraction of the cost. Weight management where relevant adds to it. Both are consistently under-prescribed. If you have not completed a proper supervised strengthening programme, that is the higher-value place to start before paying for injections.
Commonly quoted figures of six to twelve months are not consistently demonstrated across studies, and long-term benefit beyond six months is variable in the literature. Since the pooled effect versus placebo is below the clinically meaningful threshold, duration claims should be treated cautiously. If you proceed, agree a review point in advance so that whether it worked gets an honest answer rather than drifting into another course.
Sources
- Pereira TV, Jüni P, Saadat P, et al. Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis. BMJ, 2022.
- AAOS — Management of Osteoarthritis of the Knee (Non-Arthroplasty), 3rd edition, 2021.
- NICE guideline NG226 — Osteoarthritis in over 16s: diagnosis and management, 2022.
- Should intra-articular hyaluronic acid be used routinely for knee osteoarthritis pain? PMC.
- Intra-articular hyaluronic acid for knee osteoarthritis: utilisation trends amid conflicting clinical practice guidelines. PMC.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases — Osteoarthritis.
Last updated: August 2026. Written by Aisha Desai, who covers musculoskeletal topics and is not a clinician. Reviewed for accuracy by our editorial team; this article has not been reviewed by a named clinician. It is general information, not medical advice, and it is not a recommendation for or against any treatment in your case. Guidelines on this topic genuinely conflict and continue to evolve. Decisions about injections belong with the clinician who knows your imaging, history and treatment response.
